User menu

Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.

Bibliographic reference Westhovens, René ; Keyser, Filip De ; Rekalov, Dmytro ; Nasonov, Evgeny L ; Beetens, Johan ; et. al. Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.. In: Annals of the rheumatic diseases, (2012)
Permanent URL http://hdl.handle.net/2078.1/124332